Beyond VEGF and PDGF, other antiangiogenic therapies, such as MMP (matrix metalloproteinase) inhibitors and endothelial cell-targeting therapies are in the nascent stages of development for IBD treatment. This evidence concerns the gene VEGFA and inflammatory bowel disease.